Welcome to our dedicated page for Aptinyx news (Ticker: APTX), a resource for investors and traders seeking the latest updates and insights on Aptinyx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptinyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptinyx's position in the market.
Aptinyx Inc. (Nasdaq: APTX) announced significant business updates and financial results for Q4 and full year 2022. The company halted its Phase 2b study of NYX-783 for PTSD due to insufficient effectiveness, prompting a workforce reduction of approximately 60% to lower operational costs. Total cash stood at $56.2 million, down from $106.1 million in 2021. No collaboration revenue was reported for 2022, and R&D expenses decreased to $42.7 million from $55.4 million. The company's net loss improved to $64.8 million for 2022 compared to $74.9 million in the previous year, reflecting a net loss per share of $0.96.
Aptinyx announced disappointing results from its Phase 2 study of NYX-458, intended for cognitive impairment in Parkinson’s disease patients. The study revealed NYX-458 did not yield clinically meaningful improvements over placebo, leading to the decision to discontinue further development. The company plans cost-cutting measures and will terminate its NYX-783 study on PTSD to analyze existing data. The Phase 2 study involved 99 patients and assessed efficacy using various cognitive performance metrics over 12 weeks, with NYX-458 being well-tolerated but ultimately ineffective. The company aims to explore strategic alternatives.
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company, announced that CEO Andy Kidd will participate in a virtual fireside chat during the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. ET. A live webcast will be available on Aptinyx's website under the 'Events and Presentations' section and will be archived for 30 days. Aptinyx focuses on developing therapies for brain and nervous system disorders using proprietary small molecules that enhance synaptic plasticity. The company has three clinical candidates aimed at various CNS indications, including cognitive impairment and post-traumatic stress disorder.
Aptinyx Inc. (NASDAQ:APTX) announced upcoming poster presentations at the 52nd Annual Meeting of the Society for Neuroscience, scheduled for November 12-16, 2022, in San Diego, CA. These presentations will showcase preclinical data for NYX-783, a positive allosteric modulator targeting NMDA receptors, focusing on its potential in treating post-traumatic stress disorder and opioid use disorder. The notable presentations include those by Joanna Dabrowska and Katie Leaderbrand, highlighting significant advancements in preclinical evaluations.
Aptinyx Inc. (Nasdaq: APTX) reported its Q3 2022 financial results, highlighting a net loss of $15.3 million, improved from $21.2 million in Q3 2021. The company has a cash balance of $66.5 million, projected to support operations into 2024.
Key updates include plans to report results from a Phase 2 study of NYX-458 for cognitive impairment in Parkinson's patients in 1Q 2023, and progress in enrolling patients for a Phase 2b study of NYX-783 for PTSD. Additionally, a $5.6 million NIH grant has been finalized for NYX-783's development in opioid use disorder.
Aptinyx Inc. has secured a $5.6 million grant from the NIH HEAL Initiative to advance studies of NYX-783 for treating opioid use disorder (OUD). Preclinical results indicate a promising safety profile and potential efficacy of NYX-783, prompting the initiation of a Phase 1 clinical study expected later this year. The study will assess safety, tolerability, and pharmacokinetics of NYX-783 in opioid users. Collaboration with researchers at Yale University enhances the program, which aims to address the ongoing opioid crisis affecting millions.
Aptinyx Inc. (NASDAQ: APTX) announced a conference call on November 8, 2022, at 5:00 p.m. ET to discuss its third quarter 2022 financial results and recent business highlights. The company focuses on developing therapies for brain and nervous system disorders and is advancing clinical development of two product candidates addressing cognitive impairment and post-traumatic stress disorder. A live audio webcast will be available on Aptinyx's website.
Aptinyx Inc. (NASDAQ: APTX) has completed the enrollment of 99 patients in its Phase 2 study of NYX-458, targeting cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies. The 12-week treatment period has commenced, followed by a 30-day safety follow-up. Results are anticipated in 1Q 2023. NYX-458 acts as a positive allosteric modulator of NMDA receptors, potentially addressing cognitive deficits in affected patients. Current treatment options are limited, highlighting the significance of this study.
Aptinyx Inc. (NASDAQ: APTX) announced disappointing results from its Phase 2b clinical study of NYX-2925, aimed at treating fibromyalgia. The study failed to achieve statistically significant separation from placebo on the primary endpoint—average daily pain reduction. While some improvement was noted in secondary endpoints early on, by week 12, the placebo group showed notable improvement, undermining NYX-2925's efficacy. The company will refocus efforts on other pipeline projects, including NYX-458 for cognitive impairment related to Parkinson’s disease, with data expected in Q1 next year.
